Fulgent Genetics

Q2 FY2026 EarningsQ2 FY26 results missed consensus estimates across all major financial metrics. Revenue of $85.4M was below the $94.0M expected, while the GAAP gross margin of 30.1% significantly lagged the 38.0% consensus. Diluted GAAP EPS was $(1.05) vs. $(0.72) expected. The miss was primarily driven by revenue cycle management (RCM) transition issues impacting collections, leading management to lower the full-year FY26 revenue guidance to $330M-$340M.